Quest Diagnostics Incorporated (DGX) SEC Filings & Earnings Calls
EquiReason read 15 Quest Diagnostics Incorporated SEC filings in the last 12 months. Latest: 10-Q on 2026-10-23 — Quest Diagnostics reported strong Q3 2026 results with 10% revenue growth, 180bps operating margin expansion, and 28.7% EPS growth..
Source: SEC EDGAR filings · figures as of 2026-09-30 · read by EquiReason
- Market cap
- 26.6B
- P/E TTM
- 24.1
- Dividend yield
- 1.4%
- 52-week
- —
- Next earnings
- 8 Feb, in 107 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
23 Oct 202610-QQuest Diagnostics reported strong Q3 2026 results with 10% revenue growth, 180bps operating margin expansion, and 28.7% EPS growth.earningsopen
Figures in the filing · each found in the filing text
| Net revenues · Q3-2026 | $3.10B | +10% y/y |
| DIS revenues · DIS · Q3-2026 | $3.04B | +10% y/y |
| Requisition volume change · DIS · Q3-2026 | 14.5% | |
| Organic requisition volume change · DIS · Q3-2026 | 14.4% | |
| Revenue per requisition change · DIS · Q3-2026 | -4.2% | |
| Operating income · Q3-2026 | $479M | +24% y/y |
| Net income attributable to Quest Diagnostics · Q3-2026 | $312M | +27% y/y |
| Diluted earnings per share · Q3-2026 | $2.78 | +29% y/y |
| Net cash provided by operating activities · Q3-2026 | $611M | +9% y/y |
| Capital expenditures · Q3-2026 | $166M | +15% y/y |
Risks flagged
Revenue per requisition decline from business mix
“Revenue per requisition decreased by 4.2% compared to the prior year period primarily driven by the business mix associated with our new relationships with Corewell Health and Fresenius Medical Care, which include a greater proportion of routine tests than most of our clinical testing.” · word for word
Labor cost inflation
“The increase was primarily driven by higher compensation costs and, to a lesser extent, an increase in supplies expense reflecting higher testing volumes, partially offset by cost savings and productivity improvements from our Invigorate program.” · word for word
Legal and regulatory exposure
“adverse results from pending or future government investigations, lawsuits or private actions” · word for word
22 Oct 20268-K · 2.02Raised FY26 revenue guidance to $12.065-12.105B from $11.95-12.05B; raised adjusted EPS to $11.25-11.35 from $11.05-11.25; strong Q3 results with 10% revenue growth and 15.4% adjusted EPS growth.open
Figures in the filing · each found in the filing text
| Net revenues · Q3-2026 | $3.10B | +10% y/y |
| Diagnostic Information Services revenues · Diagnostic Information Services · Q3-2026 | $3.04B | +10% y/y |
| Revenue per requisition change · Q3-2026 | -4.2% | |
| Requisition volume change · Q3-2026 | 14.5% | |
| Organic requisition volume change · Q3-2026 | 14.4% | |
| Operating income · Q3-2026 | $479M | +24% y/y |
| Operating income as a percentage of net revenues · Q3-2026 | 15.5% | |
| Net income attributable to Quest Diagnostics · Q3-2026 | $312M | +27% y/y |
| Diluted EPS · Q3-2026 | $2.78 | +29% y/y |
| Adjusted diluted EPS · Q3-2026 | $3.00 | +15% y/y |
Guidance
FY26 revenue raised to $12.065-12.105B from $11.95-12.05B; FY26 adjusted EPS raised to $11.25-11.35 from $11.05-11.25; FY26 reported EPS $10.21-10.31 from $9.97-10.17; FY26 operating cash flow ~$1.90B from ~$1.80B; capex ~$550M unchanged
Raised FY26 revenue and EPS guidance on strong organic growth and productivity gains
Risks flagged
Revenue per requisition declining 4.2% YoY, indicating pricing pressure or mix shift
“Revenue per requisition (4.2)% change year-over-year”
Capital expenditures increasing 15% YoY, potentially pressuring free cash flow
“Capital expenditures $166 million vs $144 million prior year, up 15.0%”
22 Oct 20268-K · 8.01Unauthorized access to Quanum LSM system; patient records accessed; investigation ongoing; no material business disruption yet.open
Risks flagged
Potential regulatory fines, litigation, and reputational damage from data breach
“unauthorized party accessed certain patient records; investigation ongoing”
6 Oct 20268-K · 5.02Quest Diagnostics announced EVP Catherine Doherty will retire in July 2027; transitions to new role with health systems and modernization projects. No change in compensation.open
Risks flagged
Low risk; retirement planned well in advance, no sudden departure
“Retirement announced ~9 months in advance; transition role defined”
23 Jul 20268-K · 2.02Quest Diagnostics reported Q2 2026 revenues of $3.04B (+10.2% YoY), adjusted EPS $3.12 (+19.1% YoY), and raised full-year revenue and EPS guidance, indicating strong demand and operational execution.earningsopen
Figures in the filing · each found in the filing text
| Net revenues · Q2-2026 | $3.04B | +10% y/y |
| Diagnostic Information Services revenues · Diagnostic Information Services · Q2-2026 | $2.98B | +10% y/y |
| Revenue per requisition change · Q2-2026 | -2.8% | |
| Requisition volume change · Q2-2026 | 13.1% | |
| Organic requisition volume change · Q2-2026 | 13.0% | |
| Operating income · Q2-2026 | $459M | +5% y/y |
| Operating income as a percentage of net revenues · Q2-2026 | 15.1% | |
| Net income attributable to Quest Diagnostics · Q2-2026 | $320M | +13% y/y |
| Diluted EPS · Q2-2026 | $2.84 | +15% y/y |
| Adjusted diluted EPS · Q2-2026 | $3.12 | +19% y/y |
Guidance
FY26 revenue raised to $11.95-12.05B from $11.78-11.90B; FY26 reported EPS $9.97-10.17 from $9.58-9.78; FY26 adjusted EPS $11.05-11.25 from $10.63-10.83; FY26 operating cash flow ~$1.80B from ~$1.75B; FY26 capex ~$550M unchanged
Guidance raised on strong Q2 performance, reflecting sustained demand and operational leverage.
Risks flagged
Revenue per requisition declined 2.8% YoY, indicating potential pricing pressure or mix shift.
“Revenue per requisition (2.8)%” · word for word
Operating margin slightly compressed (15.1% vs 15.9% reported; 16.5% vs 16.9% adjusted), suggesting cost pressures.
“Operating income as a percentage of net revenues 15.1% vs 15.9%”
23 Jul 202610-QQuest Diagnostics reported strong Q2 2026 results with revenue up 10.2% YoY, EPS up 15%, driven by volume growth and operational efficiency.earningsopen
Figures in the filing · each found in the filing text
| Net revenues · Q2-2026 | $3.04B | +10% y/y |
| DIS revenues · Diagnostic Information Services · Q2-2026 | $2.98B | +10% y/y |
| Net income attributable to Quest Diagnostics · Q2-2026 | $320M | +13% y/y |
| Diluted earnings per share · Q2-2026 | $2.84 | +15% y/y |
| Net cash provided by operating activities · Q2-2026 | $597M | +10% y/y |
| Capital expenditures · Q2-2026 | $138M | +28% y/y |
| DIS requisition volume change · Diagnostic Information Services · Q2-2026 | 13.1% | |
| DIS revenue per requisition change · Diagnostic Information Services · Q2-2026 | -2.8% |
Risks flagged
Revenue per requisition pressure from business mix
“Revenue per requisition decreased by 2.8% compared to the prior year period primarily driven by the business mix associated with our new relationships with Corewell Health and Fresenius Medical Care” · word for word
Compensation cost inflation
“The increase was primarily driven by higher compensation costs” · word for word
Reimbursement pressure
“The Invigorate program aims to deliver 3% annual cost savings and productivity improvements to partially offset pressures from the current inflationary environment, including labor and benefit cost increases and reimbursement pressures.” · word for word
22 Apr 202610-QNet revenues $2.90B (+9% y/y); DIS revenues $2.83B (+9% y/y); Requisition volume change 10.9; Guidance: Capex guided ~$550M for FY2026open
Figures in the filing · each found in the filing text
| Net revenues · Q1-2026 | $2.90B | +9% y/y |
| DIS revenues · DIS · Q1-2026 | $2.83B | +9% y/y |
| Requisition volume change · DIS · Q1-2026 | 10.9% | |
| Organic requisition volume change · DIS · Q1-2026 | 10.8% | |
| Revenue per requisition change · DIS · Q1-2026 | -1.3% | |
| Operating income · Q1-2026 | $399M | +16% y/y |
| Net income attributable to Quest Diagnostics · Q1-2026 | $252M | +14% y/y |
| Diluted earnings per share · Q1-2026 | $2.24 | +16% y/y |
| Net cash provided by operating activities · Q1-2026 | $278M | -12% y/y |
| Capital expenditures · Q1-2026 | $114M | -3% y/y |
Guidance
Capex guided ~$550M for FY2026
No explicit revenue or earnings guidance provided; capex guidance of ~$550M for 2026.
Risks flagged
Reimbursement pressure
“The Invigorate program aims to deliver 3% annual cost savings and productivity improvements to partially offset pressures from the current inflationary environment, including labor and benefit cost increases and reimbursement pressures.” · word for word
Business mix dilution from new relationships
“Revenue per requisition decreased by 1.3% compared to the prior year period primarily driven by the business mix associated with our new relationships with Corewell Health and Fresenius Medical Care, which include a greater proportion of routine tests than most of our clinical testing.” · word for word
21 Apr 20268-K · 2.02Net revenues $2.90B (+9% y/y); Diagnostic Information Services revenues $2.83B (+9% y/y); Requisition volume 10.9; Guidance: Revenue guidance raised by ~$80M at midpoint; adjusted EPS guidance raised by ~$0.13 at midpointearningsopen
Figures in the filing · each found in the filing text
| Net revenues · Q1-2026 | $2.90B | +9% y/y |
| Diagnostic Information Services revenues · Diagnostic Information Services · Q1-2026 | $2.83B | +9% y/y |
| Requisition volume · Q1-2026 | 10.9% | |
| Organic requisition volume · Q1-2026 | 10.8% | |
| Reported diluted EPS · Q1-2026 | $2.24 | +16% y/y |
| Adjusted diluted EPS · Q1-2026 | $2.50 | +13% y/y |
| Cash provided by operations · Q1-2026 | $278M | -12% y/y |
| Capital expenditures · Q1-2026 | $114M | -2% y/y |
| Net revenues guidance (low) · FY2026 | $11.78B | |
| Net revenues guidance (high) · FY2026 | $11.90B |
Guidance
Revenue guidance raised by ~$80M at midpoint; adjusted EPS guidance raised by ~$0.13 at midpoint
Full year 2026 guidance raised across revenue and EPS; strong Q1 performance drives optimism.
Risks flagged
Cash from operations declined 11.6% year-over-year despite revenue growth, indicating potential working capital pressure.
“Cash provided by operations $278 million in Q1 2026 vs $314 million in Q1 2025, down 11.6%.”
6 Apr 2026DEF 14AProxy statement filed for 2026 annual meeting, disclosing executive compensation structure and 2025 performance.open
Figures in the filing · each found in the filing text
| Net revenues · FY2025 | $11.04B | +12% y/y |
| Diluted earnings per share · FY2025 | $8.75 | |
| Adjusted diluted earnings per share · FY2025 | $9.85 | +10% y/y |
| Cash provided by operations · FY2025 | $1.89B | |
| Operating income as a percentage of net revenues · FY2025 | 14.1% | |
| Adjusted operating income as a percentage of net revenues · FY2025 | 15.9% | |
| Net income attributable to Quest Diagnostics · FY2025 | $992M | |
| Adjusted net income attributable to Quest Diagnostics · FY2025 | $1.12B | |
| Common stock repurchases · FY2025 | $450M | |
| Co-Lab Solutions revenue and management fees · Collaborative Lab Solutions · FY2025 | $800M |
Risks flagged
Data breach litigation
“Lawsuits related to a major 2019 data breach continued into 2025. The data breach exposed the personal, medical, and financial information of 12 million patients through a third-party vendor, American Medical Collection Agency (AMCA).” · word for word
Government healthcare legislation impact
“During its Q2 2025 earnings call, Quest Diagnostics highlighted potential future challenges, including the impact of government healthcare legislation (referred to as the 'One Big Beautiful Bill,' which could result in more uninsured patients) and the effects of tariffs from China and Europe on the bottom line.” · word for word
26 Feb 202610-KNet revenues $11.04B (+12% y/y); DIS revenues $10.79B (+12% y/y); DS revenues $250M (-3% y/y); Guidance: OBBBA and PTC expiration could reduce revenues by 50-60 bps by 2028; Invigorate program targets 3% annual cost savingsopen
Figures in the filing · each found in the filing text
| Net revenues · FY2025 | $11.04B | +12% y/y |
| DIS revenues · DIS · FY2025 | $10.79B | +12% y/y |
| DS revenues · DS · FY2025 | $250M | -3% y/y |
| Revenue per requisition change · DIS · FY2025 | 0.1% | |
| Requisition volume change · DIS · FY2025 | 12.3% | |
| Organic requisition volume change · DIS · FY2025 | 3.4% | |
| Operating income · FY2025 | $1.56B | +16% y/y |
| Net income attributable to Quest Diagnostics · FY2025 | $992M | +14% y/y |
| Diluted earnings per share · FY2025 | $8.75 | +14% y/y |
| Net cash provided by operating activities · FY2025 | $1.89B | +41% y/y |
Guidance
OBBBA and PTC expiration could reduce revenues by 50-60 bps by 2028; Invigorate program targets 3% annual cost savings
Organic volume growth accelerating, but reimbursement and regulatory headwinds persist; Invigorate program aims to offset cost pressures.
Risks flagged
Reimbursement Pressure
“Increased pricing pressure from customers, including payers and patients, and changing relationships with customers, payers, suppliers or strategic partners.” · word for word
Labor Cost Inflation
“Inflationary pressures, along with the competition for labor, have also resulted in a rise of our labor costs, which include the costs of compensation, benefits and recruiting and training new hires.” · word for word
Regulatory Impact from OBBBA
“We currently estimate that for 2026 through 2028 the OBBBA and the expiration of the enhanced PTCs could reduce our consolidated revenues by up to 50-60 basis points by 2028, compared to 2025.” · word for word
Cybersecurity Breach
“A breach or attack affecting third parties with whom we engage could also harm our business, results of operations and reputation and subject us to liability.” · word for word
DS Segment Decline
“DS revenues for the year ended December 31, 2025 decreased by 3.3% compared to the prior year primarily due to lower revenues associated with our risk assessment services offered to insurers.” · word for word
10 Feb 20268-K · 2.02, 8.01Revenue $2.81B (+7% y/y); Diluted EPS $2.18 (+12% y/y); Adjusted diluted EPS $2.42 (+8% y/y); Guidance: 2026 revenue $11.70B-$11.82B; adjusted EPS $10.50-$10.70earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $2.81B | +7% y/y |
| Diluted EPS · Q4-2025 | $2.18 | +12% y/y |
| Adjusted diluted EPS · Q4-2025 | $2.42 | +9% y/y |
Guidance
2026 revenue $11.70B-$11.82B; adjusted EPS $10.50-$10.70
2026 guidance reflects continued confidence in business strengths and market fundamentals.
Risks flagged
Forward-looking statements subject to risks and uncertainties.
“Forward-looking statements section.” · word for word
12 Jan 20268-K · 2.02, 7.01Advanced diagnostics revenue $1.00B; Guidance: 4-5% revenue CAGR, 7-9% adjusted EPS CAGR beyond 2025earningsopen
Figures in the filing · each found in the filing text
| Advanced diagnostics revenue · FY2025 | $1.00B |
Guidance
4-5% revenue CAGR, 7-9% adjusted EPS CAGR beyond 2025
Long-term growth outlook reaffirmed; advanced diagnostics driving demand.
Risks flagged
Forward-looking statements subject to risks; competitive and regulatory uncertainties.
“Safe harbor disclosure” · word for word
Government contract awards
federal awards · contract value, often multi-year| Date | Agency | Value | What for |
|---|---|---|---|
| 2026-10-01 | Department of Veterans Affairs | $7M | FY27 TASK ORDER - 10/1/2026 - 6/30/2027 |
Quest Diagnostics Incorporated — questions
- What did Quest Diagnostics Incorporated file recently?
- 15 SEC filings in the last 12 months. Latest: 10-Q on 2026-10-23 — Quest Diagnostics reported strong Q3 2026 results with 10% revenue growth, 180bps operating margin expansion, and 28.7% EPS growth.
Every figure on this page comes from Quest Diagnostics Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.